Literature DB >> 26482613

Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression.

Meimei Bu1, Yizhen Shen2, William L Seeger3, Shizhi An1, Rongqin Qi1, Joanna A Sanderson3, Yan Cai4.   

Abstract

Ovarian carcinoma is one of the most severe cancers in women, with a high relapse rate and limited secondary treatment options. To assist research in novel treatment technologies, including CD8(+) T cell-base immunotherapy, we examined the effect of tumor-infiltrating regulatory T cells (Tregs) in inhibiting CD8(+) T cell inflammation. We found that compared to their peripheral blood counterparts, tumor-infiltrating Tregs exhibited more potent inhibitory function, which was associated with higher interleukin 10 (IL-10) production in tumor-infiltrating Tregs. Blockade of T cell immunoglobulin mucin 3 (TIM3), a regulatory molecule overrepresented on tumor-infiltrating Tregs, had significantly reverted Treg-mediated suppression. Moreover, expression of TIM3 on tumor-infiltrating Tregs was directly correlated with tumor size. Together, our results demonstrated that ovarian tumor-infiltrating Treg cells were more immunosuppressive than their peripheral blood counterparts in a TIM3-dependent fashion.

Entities:  

Keywords:  Ovarian cancer; Regulatory T cell; TIM3; Tumor-infiltrating lymphocyte

Mesh:

Substances:

Year:  2015        PMID: 26482613     DOI: 10.1007/s13277-015-4237-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  25 in total

1.  CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells.

Authors:  Pau Serra; Abdelaziz Amrani; Jun Yamanouchi; Bingye Han; Shari Thiessen; Toshihiro Utsugi; Joan Verdaguer; Pere Santamaria
Journal:  Immunity       Date:  2003-12       Impact factor: 31.745

Review 2.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

3.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

4.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

Authors:  Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

5.  Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.

Authors:  A J Robert McGray; Robin Hallett; Dannie Bernard; Stephanie L Swift; Ziqiang Zhu; Florentina Teoderascu; Heather Vanseggelen; John A Hassell; Arthur A Hurwitz; Yonghong Wan; Jonathan L Bramson
Journal:  Mol Ther       Date:  2013-10-23       Impact factor: 11.454

6.  Modulation of tryptophan catabolism by regulatory T cells.

Authors:  Francesca Fallarino; Ursula Grohmann; Kwang Woo Hwang; Ciriana Orabona; Carmine Vacca; Roberta Bianchi; Maria Laura Belladonna; Maria Cristina Fioretti; Maria-Luisa Alegre; Paolo Puccetti
Journal:  Nat Immunol       Date:  2003-10-26       Impact factor: 25.606

7.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

8.  Cancer survival in five continents: a worldwide population-based study (CONCORD).

Authors:  Michel P Coleman; Manuela Quaresma; Franco Berrino; Jean-Michel Lutz; Roberta De Angelis; Riccardo Capocaccia; Paolo Baili; Bernard Rachet; Gemma Gatta; Timo Hakulinen; Andrea Micheli; Milena Sant; Hannah K Weir; J Mark Elwood; Hideaki Tsukuma; Sergio Koifman; Gulnar Azevedo E Silva; Silvia Francisci; Mariano Santaquilani; Arduino Verdecchia; Hans H Storm; John L Young
Journal:  Lancet Oncol       Date:  2008-07-17       Impact factor: 41.316

9.  Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment.

Authors:  Chindu Govindaraj; Karen Scalzo-Inguanti; Mutsa Madondo; Julene Hallo; Katie Flanagan; Michael Quinn; Magdalena Plebanski
Journal:  Clin Immunol       Date:  2013-07-25       Impact factor: 3.969

10.  Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.

Authors:  S Read; V Malmström; F Powrie
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

View more
  25 in total

1.  Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis.

Authors:  Luigi Cari; Giuseppe Nocentini; Graziella Migliorati; Carlo Riccardi
Journal:  Oncoimmunology       Date:  2017-11-09       Impact factor: 8.110

Review 2.  Modulation of regulatory T cell function and stability by co-inhibitory receptors.

Authors:  Liliana E Lucca; Margarita Dominguez-Villar
Journal:  Nat Rev Immunol       Date:  2020-04-08       Impact factor: 53.106

Review 3.  Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.

Authors:  Kristian M Hargadon
Journal:  Clin Transl Med       Date:  2020-01

4.  Human lung tumor FOXP3+ Tregs upregulate four "Treg-locking" transcription factors.

Authors:  Tatiana Akimova; Tianyi Zhang; Dmitri Negorev; Sunil Singhal; Jason Stadanlick; Abhishek Rao; Michael Annunziata; Matthew H Levine; Ulf H Beier; Joshua M Diamond; Jason D Christie; Steven M Albelda; Evgeniy B Eruslanov; Wayne W Hancock
Journal:  JCI Insight       Date:  2017-08-17

Review 5.  A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.

Authors:  Prabhakaran Kumar; Palash Bhattacharya; Bellur S Prabhakar
Journal:  J Autoimmun       Date:  2018-08-31       Impact factor: 7.094

Review 6.  Role of TIM-3 in ovarian cancer.

Authors:  Y Xu; H Zhang; Y Huang; X Rui; F Zheng
Journal:  Clin Transl Oncol       Date:  2017-03-29       Impact factor: 3.405

Review 7.  Tim-3 and its role in regulating anti-tumor immunity.

Authors:  Madhumita Das; Chen Zhu; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

8.  Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity.

Authors:  Peter C Hart; Preety Bajwa; Hilary A Kenny
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions.

Authors:  Keiko Nagahara; Tomohiro Arikawa; Souichi Oomizu; Keiichi Kontani; Atsuya Nobumoto; Hiroaki Tateno; Kota Watanabe; Toshiro Niki; Shigeki Katoh; Minoru Miyake; Syun-Ichiro Nagahata; Jun Hirabayashi; Vijay K Kuchroo; Akira Yamauchi; Mitsuomi Hirashima
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

10.  Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients.

Authors:  Zhuqing Liu; Elizabeth L McMichael; Gulidanna Shayan; Jing Li; Kevin Chen; Raghvendra Srivastava; Lawrence P Kane; Binfeng Lu; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2018-04-30       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.